97 results about "Chronic glomerulonephritis" patented technology

The invention belongs to the technological field of the Chinese medicine, particularly relating to an extraction and separation processes of the active ingredients with the active function of treating the chronic glomerulonephritis. The mullein indican is the active compound researched and developed for many years in our research institute; the mullein indican is extracted, separated and refined from the digitalis leaf and is an active compound with the function of treating the chronic glomerulonephritis. The invention is the research result of many years held and developed by the Chinese Medicine Research Department of the Chinese Medicine Research Institute of China and is supported by the special fund of the Central Institute of the National Science and Technology Department; now the compound has been approved by the State Food and Drug Administration Bureau as the novel drug and the mechanism research of the treatment of the chronic nephritis has been completed; the pre-clinical research work includes the main pharmacodynamic experiment, the production technology experiment (including the industrialized extraction and separation processes), the quality control standard, the experiment of the affecting factors of the quality, the experiment of the long-term stability, the acute toxicity of the rat, the experiment of the long-term toxicity, the teratogenic and mutagenic experiment, the general pharmacological experiment, the pharmacokinetics experiment, and so on. The digitalis leaf is mainly produced in the Huaiqing area of the Henan province, and is also grown wild and cultivated in the Shaanxi, Hebei and other places of China.

An extract of rehmannia leaf used for preparing the medicines and health-care food to prevent and treat the renal function diseases, such as albuminuria, hematuria, chronic glomerulonephritis is disclosed. Its preparing process is also disclosed.

The invention relates to a traditional Chinese drug for treating chronic glomerulonephritis. The traditional Chinese drug is made from the following bulk drugs by weight: 30-40g of raw hoantchy root, 12-15g of dangshen, 12-15g of cherokee rose, 12-15g of gordon euryale seed, 20-25g of prepared rhizome of rehmannia, 12-15g of pulp of dogwood fruit, 20-30g of fried yam, 20-30g of tuckahoe, 20- 30g of fried atractylodes rhizome, 30-40g of motherwort, 20-30g of black bean, 6-9g of roasted liquoric root, 25-30g of plantain seed and 30-40g of field thistle. The traditional Chinese drug has the advantages of simple preparation, low cost, wide drug sources, convenient use, fast curative effect, high curative ratio and no toxic and side effect, and clinical application proves that the curative ratio is 60% and the effective rate is 90% .

The invention discloses a traditional Chinese medicine composition for treating chronic nephritis proteinuria, and the traditional Chinese medicine composition is mainly prepared by the following active pharmaceutical ingredients in parts by weight: 20-50 parts of raw membranous milkvetch root, 15-30 parts of pilose Asiabell root, 15-30 parts of Chinese peashrub root, 15-30 parts of raw coix seedroot, 18-30 parts of fructus forsythiae, 12-30 parts of honeysuckle flower, 18-30 parts of heartleaf houttuynia herb, 15-30 parts of spreading hedyotis herb, 9-20 parts of Szechuan lovage rhizome, 9-20 parts of tree peony bark, 15-30 parts of motherwort herb, 15-30 parts of Indian buead, 15-30 parts of corn silk and 15-30 parts of winged euonymus twig. In addition, the invention further disclosesa preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition can combine tonification with purgation, perform warming and cooling simultaneously,effectively eliminate the proteinuria and other pathological indicators of kidneys, delay and even block the progress of chronic nephritis and realize the significant protection effect for the kidneys.

A composition for repressing transformation growth factor β contains theanine as an active substance. The composition is useful for preventing or treating chronic glomerulonephritis, renal interstitial fibrosis, hepatic fibrosis, hepatic cirrhosis, idiopathic interstitial pneumonia, keloid, hidebound disease, arterial sclerosis, myocardial infarction, cardiac fibrosis, restenosis, acute megakaryoblastic leukemia, adult T-cell leukemia, chronic fatigue syndrome or ordinary fatigue.

The invention relates to application of evodiamine in preparing a medicine for inhibiting an aryl hydrocarbon receptor. The medicine for inhibiting the aryl hydrocarbon receptor has the anti-tumor and immunoregulation effects by inhibiting the aryl hydrocarbon receptor, wherein the tumors are breast cancer, endometrial cancer, prostate cancer, lung cancer, gastric cancer, liver cancer, colon cancer and the like; and the immunoregulation is performed aiming at various inflammatory related diseases, such as sepsis, sepsis shock, rheumatic arthritis, rheumatoid arthritis, asthma, acute and chronic glomerulonephritis, and systemic lupus erythematosus. In the application, the evodiamine is an alkaloid component in a traditional Chinese medicine, namely medicinal evodia fruit, has the molecular formula of C19H17NO3 and the molecular weight of 303.4Da, is insoluble, can be dissolved in organic solvents such as dimethyl sulfoxide, ethanol, diethyl ether and chloroform, and has the melting point of 278 to 279 DEG C.

The invention discloses application of a Chinese medicinal composition in preparing a medicament for treating chronic glomerulonephritis. The Chinese medicinal composition consists of eight gouts of Chinese medicaments such as astragalus root, steatite, selfheal, and the like. The medicinal composition has the efficacies of promoting qi transformation, promoting diuresis and softening hardness to dissipate stagnation. The clinical research shows that the Chinese medicinal composition can effectively treat the chronic glomerulonephritis.

The invention discloses a traditional Chinese medicinal composition for treating chronic glomerulonephritis, and belongs to the technical field of traditional Chinese medicines. The c traditional Chinese medicinal composition is prepared through using the following raw medicines, by weight, 25-35 parts of Radix Astragali, 12-18 parts of Chinese yam, 8-12 parts of Polygonatum sibiricum, 8-12 parts of Poria cocos, 12-18 parts of Semen Euryales, 18-22 parts of Cogongrass rhizome, 3-8 parts of Japanese Thistle Herb, 3-8 parts of Panax Notoginseng, 12-18 parts of honeysuckle flower, 12-18 parts of raw rehmannia root, 8-12 parts of Cortex Moutan, 18-22 parts of Fructus Rosae Laevigatae, 18-22 parts of coix seed and 8-12 parts of Amur Corktree Bark. The traditional Chinese medicinal composition which is composed of pure traditional Chinese medicines has small toxic side effects and substantial treatment effects, has a curing rate of 96% and an effective rate of 100%.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 6-40 parts of rheum officinale, 10-95 parts of astragalus and 5-65 parts of salvia miltiorrhiza by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.

The present invention relates to a preventive or therapeutic agent for a glomerular disease which comprises an anti-thrombocytic agent and an HMG-CoA reductase inhibitor as active ingredients. The above agent is useful for prevention and therapy of various glomerular diseases including chronic glomerular nephritis.

The present invention relates to a preventive or therapeutic agent for a glomerular disease which comprises an anti-thrombocytic agent and an HMG-CoA reductase inhibitor as active ingredients. The above agent is useful for prevention and therapy of various glomerular diseases including chronic glomerular nephritis.

The invention discloses a super-paramagnetic iron oxide nanoparticle compound as well as a preparation method and application thereof. The super-paramagnetic iron oxide nanoparticle compound is prepared by the following steps: preparing super-paramagnetic iron oxide nanoparticles by taking Fe3O4 with surface modified with a polyethylene glycol derivative as a core; and then modifying an IL-1 antibody on the surfaces of the super-paramagnetic iron oxide nanoparticles, so that the super-paramagnetic iron oxide nanoparticle compound is prepared. The super-paramagnetic iron oxide nanoparticle compound prepared by the invention can achieve specific affinity with high-expression IL-1 in mesangial area and glomerular area of chronic glomerulonephritis in vivo and can display and quantify the early lesions of the chronic glomerulonephritis in the forms of magnetic resonance images and data; therefore, the super-paramagnetic iron oxide nanoparticle compound can be used for the early diagnosis of diseases and for the dynamic monitoring of changes of nephropathy, and a magnetic resonance molecular imaging means for noninvasive and in vivo evaluation of membranous nephropathy is provided.

The invention provides antibody-modified liposome-nanoparticle hybrids (Liposome-nanoparticle hybrids, LNHy) with a lipid shell and a nanoparticle core, which take charged nanoparticles as an inner core, and a liposome phospholipid bilayer with opposite charges is coated onto the surface to form a cell-like structure with a core-shell. The hybrids have targeting ability and can encapsulate an anti-inflammatory drug and an anti-fibrosis drug which have prevention and / or treatment effects on chronic glomerulonephritis, so that the effective treatment effect of double regulation and control on chronic glomerulonephritis is realized.

The present invention relates to a medicine with the functions of supplementing qi, securing kidney, promoting blood circulation to remove stasis, clearing heat, disinhibiting dampness, regulating and supplementing spleen and kidney and regulating yin and yang in treating acute and chronic nephritis, chronic glomerulonephritis, chronic pyelonephritis and latent nephritis. Said medicine is prepared by making 8 Chinese medicinal materials of astragalus root, ginseng, cornux fruit, imperata root, phellodendron bark, smooth greenbrier root and others go through the processes of low-temp. drying, grinding and capsulizing. Its therapeutic effect is reliable, and its cure rate is above 95.2%.

The invention discloses a medicament composition and a preparation method for treating chronic glomerulonephritis. The medicament composition comprises the components of raw material medicament based on portions by weight: 450 to 550 portions of milk veteh, 200 to 300 portions of angelica, 330 to 430 portions of yam, 200 to 300 portions of bupleurum, 250 to 350 portions of pyrrosia lingua, 250 to 350 portions of umbellate pore furgus and 50 to 100 portions of leech. The medicament composition has obvious effect on treating chronic glomerulonephritis, raises high cutting and low cutting of whole blood viscosity, blood plasma and red cell accumulation, reduces the levels of the total protein and the albumin of blood, raises the levels of the nitrogen and the creatinine of blood urea, improves blood haemorheology and raises urinary output by 3h and total urinary output.

The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.

A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt / V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other / unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng / L (IQR, 2.4 to 14.0 ng / L). n-oxPTH concentrations were not different in men and women (5.9 ng / L; IQR, 2.4 to 14.2 ng / L; n=224; vs. 5.5 ng / L; IQR, 2.4 to 14.0 ng / L; n=1 16; p=0.915).

The invention relates to a pure traditional Chinese medicine preparation for treating glomerular diseases. The pure traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30 parts of membranous milkvetch root, 12 parts of amur corktree bark, 15 parts of rhubarb, 40 parts of glabrous greenbrier rhizome, 20 parts of radix salviae miltiorrhizae, 15 parts of oriental waterplantain rhizome, 20 parts of epimedium herb, 15 parts of lalang grass rhizome and 30 parts of motherwort herb, and prepared by decoction, filtration, concentration of filtrate and drying. The pure traditional Chinese medicine preparation has significant efficacy for kidney diseases comprising acute and chronic glomerulonephritis, nephrotic syndrome, hypertensive nephropathy, diabetic nephropathy and early renal insufficiency caused by various reasons; furthermore, the raw materials are easily available, the production process is simple, the toxicity and side effects are small, and the administration is convenient, thereby providing the effective pure traditional Chinese medicine preparation for treating the kidney diseases.

Disclosed is a Chinese medicinal formulation for treating chronic glomerular nephritis wherein the recipe includes eucommia bark 15g, nutgrass flatsedge rhizome 15g, psoralea fruit 15g, Achyranthes bidentatae 15g, pig's kidney 2 pieces, notoginseng 30g and astragalus root 20g. The medicament is prepared through conventional processes with easy accessibility of raw materials, simplified formulation and preparing procedures, and low cost of medicament production.

The invention relates to anti-inflammatory hexapeptide Lys, Val, Cit Lys Pro Val as well as preparation and application thereof. The invention also comprises a method for preparing the polypeptide. The method is selected from the conventional solid phase synthesis method, a synthesis method in a solution, a gene recombination method or a chemical synthesis method. The medicament is used for treating inflammatory immune relevant diseases, wherein the inflammatory relevant diseases comprise sepsis, septic shock, rheumatoid (rheumatoid) arthritis, asthma, acute and chronic glomerulonephritis, systemic lupus erythematosus, and the like.

The invention relates to the technical field of medicine. The clinical manifestations of glomerulonephritis are proteinuria, hematuria, edema, hypertension, etc. Among them, chronic glomerulonephritis has a long course of disease, often has different degrees of renal function damage, and has recurrent attacks, and the prognosis is poor. The purpose of the present invention is to provide the application of Clary sage extract in the preparation of medicine for treating glomerulonephritis. The invention provides an extract of sage ganxie obtained by drying and pulverizing medicinal materials of the roots of sage ganxie, soaking them in water-containing lower alcohol, extracting by percolation or heating, and concentrating and drying the extract. The above-mentioned Clary Sage extract has been confirmed by animal experiments to significantly reduce the urinary protein content of serum sickness glomerulonephritis model rats, and can significantly reduce the swelling of the glomerulus, and also has the ability to reduce blood viscosity and diuresis. therapeutic effect. The invention not only provides a new application for the ganxi sage, but also provides a new treatment drug for the majority of nephritis patients.

A Chinese medicine "Shuzetong" for treating chronic glomerulonephritis and nephrotic syndrome is prepared from 7 Chinese-medicinal materials including astragalus root, bugleweed, leech, imperate rhizome, etc. Its advantage is high curative effect.

The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.

The invention provides a traditional Chinese medicinal preparation for treating chronic renal disease and a preparation method thereof. The traditional Chinese medicinal preparation is prepared from the following crude medicines in parts by weight: rheum officinale and safflower on (1-10):(10-1); the crude medicines are prepared into an injection, a freeze-dried powder injection or other oral preparations through certain extraction and purification processes. Animal experiments prove that the traditional Chinese medicinal preparation can be used for significantly improving the hemorheology indexes of mice infected by chronic glomerulonephritis and reducing serum IL-6, IL-8 and TNF-alpha levels; the preparation can be used for remarkably reducing serum urea nitrogen and serum creatinine contents of mice of chronic renal failure and increasing a serum albumin content; moreover, the preparation can be used for improving the various hemorheology indexes and levels of mice of chronic renal failure; a pathological result shows that the traditional Chinese medicinal preparation disclosed by the invention can be used for improving and inhibiting damage of chronic kidney disease and chronic renal failure on kidney; furthermore, the traditional Chinese medicinal preparation prepared by the optimal preparation method disclosed by the invention is more excellent than a traditional Chinese medicinal preparation prepared by a conventional method.

The invention discloses a traditional Chinese medicinal composition for treating chronic glomerulonephritis. In Chinese medical science, chronic glomerulonephritis is thought to belong to the category of 'edema' disease, and is mainly caused by spleen and kidney deficiency, qi deficiency and blood stasis. Vital qi is deficient, blood stasis is converted into water, and pathogenic toxin is easy to invade, so that spleen and kidney are deficient for a long time and no longer recover, astringent therapy is invalid, and thus edema and proteinuria are refractory to eliminate. Therefore, traditional Chinese medicines of jasminum laurifolium, stephania tetrandra, salix hypoleuca, smooth stylose staff-tree, rhizoma corydalis, rust-colored crotalaria herb, dioscorea hemsleyi, radix boehmeriae, all-grass of redclawed habenaria, root of szechwan-Yunnan sanicle, and cypripedium margaritaceum franch are selected and decocted with water into a decoction. Through clinical tests, the total effective rate reaches 97.8%, and the treatment effect is significant.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the raw material medicines of rheum officinale and salvia miltiorrhiza in a weight ratio of 1-10:10-1 by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure; and the treatment effect of the traditional Chinese medicine preparation prepared by the preparation method provided by the invention is better than that of a traditional Chinese medicine preparation prepared by a conventional method.

The invention discloses a medicament composition and a preparation method for treating chronic glomerulonephritis. The medicament composition comprises the components of raw material medicament based on portions by weight: 450 to 550 portions of milk veteh, 200 to 300 portions of angelica, 330 to 430 portions of yam, 200 to 300 portions of bupleurum, 250 to 350 portions of pyrrosia lingua, 250 to350 portions of umbellate pore furgus and 50 to 100 portions of leech. The medicament composition has obvious effect on treating chronic glomerulonephritis, raises high cutting and low cutting of whole blood viscosity, blood plasma and red cell accumulation, reduces the levels of the total protein and the albumin of blood, raises the levels of the nitrogen and the creatinine of blood urea, improves blood haemorheology and raises urinary output by 3h and total urinary output.

The invention discloses a medicine for treating chronic glomerulonephritis and a nephrotic syndrome and a preparation method thereof. The medicine is mainly prepared from astragalus membranaceus, humifuse euphorbia herb, codonopsis pilosula, dogwood pulp, prepared rehmannia, white atractylodes rhizome, poria cocos and rhizoma alismatis. The prepared medicine has the effects of strengthen the spleen, tonifying the kidney, invigorating Yang, consolidating vital energy, clearing damp and promoting diuresis, and can reduce proteinuria and hematuria to treat the chronic nephritis and the nephrotic syndrome; the medicine is applicable to treatment of proteinuria and hematuria caused by the chronic nephritis and the nephrotic syndrome, and in the traditional Chinese medicine, the syndrome includes spleen deficiency, kidney deficiency, Qi deficiency and damp turbidity.

The present invention discloses one kind of nephropathy treating medicine composition and its preparation process. The Chinese medicine composition is prepared with Nippon yam rhizome, bupleurum root, angelica, astragalus root and leech. It is used in treating mesenchymal disease of glomerulum and renaltubule, chronic glomerulonephritis, renal disease, nephritic syndrome, etc. It has determined curative effect.

The invention discloses the application of the combination of prince feather and fleabane in preparing medicaments for curing kidney diseases. The kidney diseases include nephritis, nephropathy syndrome, chronic renal failure, diabetes, nephropathy, chronic glomerulonephritis and so on. The combination of prince feather and fleabane is prepared as follows: Chinese traditional medicaments, namely prince feather and fleabane, are combined; the combined prince feather and fleaban are extracted, or the prince feather and the fleabane are extracted separately. The invention provides a new medicinal use of the combination of prince feather and fleabane, namely the application of the combination in preparing medicaments for curing kidney diseases. Proven through animal experiments, the combination of the prince feather and the fleabane has true curative effect on cure of kidney diseases, and provides a new medicine for curing kidney diseases and a new option for sufferers.